Cheesecake Factory, Coors Cite Weight Loss Drugs as New Risk

The Cheesecake Factory, Inc. and Keurig Dr Pepper, Inc. are among businesses warning investors in their annual reports that weight loss drugs that curb appetites also pose a risk to curbing their sales.

Keurig Dr Pepper said in its 10-K annual report Tuesday that its financial results could be impacted by new consumer preferences, including the use of weight loss drugs. The Cheesecake Factory made a similar disclosure in its annual report Monday, noting that “new and current medical treatments such as GLP-1 agonists may shift consumer preferences.”

GLP-1 agonists like brand-name Ozempic, a class of medications used to treat ...